Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Inclusion Criteria:

* Males and females of at least 18 years of age with stage IV or unresectable stage III non-ocular melanoma who may have received 0 to 2 prior regimens for metastatic disease with a biological therapy or immunotherapy (e.g., IL-2 or interferon-alfa).
* Measurable disease according to Response Criteria for Solid Tumors (RECIST).
* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1.
* Estimated survival is greater or equal to 4 months.
* Negative pregnancy test (women of childbearing potential only).
* Pretreatment laboratory levels that meet specific criteria.
* Signed informed consent, including permission to use protected health information.

Exclusion Criteria:

* Prior treatment with M200 or a5b1 inhibitors and murine or chimeric monoclonal antibodies.
* Prior treatment with DTIC, temozolomide, or other chemotherapeutic regimens.
* Known sensitivity to murine proteins or chimeric antibodies or other components of the product.
* Use of any investigational drug within 4 weeks prior to screening or 5 half-lives of the prior investigational drug (whichever is longer).
* Systemic biologic, immunotherapy, and/or radiation therapy within 4 weeks of the first dose of M200.
* Documented central nervous system (CNS) tumor or CNS metastasis.
* History of thromboembolic events and bleeding disorders within the past year.
* Medical conditions that may be exacerbated by bleeding.